The short version of clinical endpoint fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Y chromosome One of two sex chromosomes present in organisms which use the XY sex-determination system. The Y chromosome is found only in males and is typically much smaller than its counterpart, the X chromosome.
The signal change manifests itself in an increase or decrease in the current (electrical) or in a change in the intensity or wavelength of the fluorescence emission (optical). Depending on the type of application, both electrical or optical signal transmission can be advantageous. For sensitive measurement of electronic changes, field-effect transistors (FET) are often used in which the flow of charges within the SWCNTs is measured. The FET structures allow easy on-chip integration and can be parallelized to detect multiple target analytes simultaneously. However, such sensors are more invasive for in vivo applications, as the entire device has to be inserted into the body. Optical detection with semiconducting SWCNTs is based on the radiative recombination of excitons in the near-infrared (NIR) by prior optical (fluorescence) or electrical excitation (electroluminescence). The emission in the NIR enables detection in the biological transparency window, where optical sensor applications benefit from reduced scattering and autofluorescence of biological samples and consequently a high signal-to-noise ratio. Compared to optical sensors in the UV or visible range, the penetration depth in biological tissue is also increased. In addition to the advantage of a contactless readout SWCNTs have excellent photostability, which enables long-term sensor applications. Furthermore, the nanoscale size of SWCNTs allows dense coating of surfaces which enables chemical imaging, e.g. of cellular release processes with high spatial and temporal resolution.
In contrast to the maternal bond, paternal bonds tend to vary over the span of a child's development in terms of both strength and stability. In fact, many children now grow up in fatherless households and do not experience a paternal bond at all. In general, paternal bonding is more dominant later in a child's life after language develops. Fathers may be more influential in play interactions as opposed to nurturance interactions. Father–child bonds also tend to develop with respect to topics such as political views or money, whereas mother–child bonds tend to develop in relation to topics such as religious views or general outlooks on life. In 2003, a researcher from Northwestern University in Illinois found that progesterone, a hormone more usually associated with pregnancy and maternal bonding, may also control the way men react towards their children. Specifically, they found that a lack of progesterone reduced aggressive behavior in male mice and stimulated them to act in a fatherly way towards their offspring.
Charged analytes have a more complex interaction in the capillary because they exhibit electrophoretic mobility, engage in electrostatic interactions with the micelle, and participate in hydrophobic partitioning. The fraction of the sample in the aqueous phase,
==== South Africa ==== The first mummy to be discovered in South Africa was found in the Baviaanskloof Wilderness Area by Dr. Johan Binneman in 1999. Nicknamed Moses, the mummy was estimated to be around 2,000 years old. After being linked to the indigenous Khoi culture of the region, the National Council of Khoi Chiefs of South Africa began to make legal demands that the mummy be returned shortly after the body was moved to the Albany Museum in Grahamstown.
Sources: en.wikipedia.org
Most of this debt was unrelated to the federally funded pandemic unemployment programs that had experienced most of the fraud, and instead was due to longstanding underfunding and California's high rate of unemployment during the pandemic.
Lipopolysaccharide binding protein (LBP) is a protein that in humans is encoded by the LBP gene. LBP is a soluble acute-phase protein that binds to bacterial lipopolysaccharide (or LPS) to elicit immune responses by presenting the LPS to important cell surface pattern recognition receptors called CD14 and TLR4. The protein encoded by this gene is involved in the acute-phase immunologic response to gram-negative bacterial infections. Gram-negative bacteria contain a glycolipid, lipopolysaccharide (LPS), on their outer cell wall. Together with bactericidal permeability-increasing protein (BPI), the encoded protein binds LPS and interacts with the CD14 receptor, probably playing a role in regulating LPS-dependent monocyte responses. Studies in mice suggest that the encoded protein is necessary for the rapid acute-phase response to LPS but not for the clearance of LPS from circulation. This protein is part of a family of structurally and functionally related proteins, including BPI, plasma cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP). Finally, this gene is found on chromosome 20, immediately downstream of the BPI gene.
=== Side effects === Side effects in animals include transient hypertension and hypotension. Xylazine decreases both respiration rate and minute ventilation, although the changes to PaCO2 and PaO2 are minor and innocuous. Xylazine has been demonstrated to reduce the dose of epinephrine that causes arrythmia in dogs anaesthetised with isoflurane and halothane. Xylazine administration in sheep activates pulmonary macrophages that damage the capillary endothelium and alveolar type I cells. This in turns causes alveolar haemorrhage and oedema causing hypoxaemia. Intracarotid administration can cause seizures and excitement in horses. Xylazine has been shown to cause myometrial contractions in pregnant cattle. Further evidence of xylazine's effect on pregnant animals is lacking and although other a2 adrenergic receptor agonists have been shown to not cause the same myometrial contraction the administration of a2 adrenergic receptor agonists is not recommended and for animals near-term should only be used in specific circumstances. Xylazine affects the glucose level via the activation of alpha2A andrenergic receptors on beta cells, which prevents insulin release. alpha2 adrenergic receptors have been reported to cause transient hyperglycaemia with xylazine being reported as a cause in cattle and equine. The renal threshold for glucose is not exceeded due to the hyperglycaemia with clinical doses. An alpha2 adrenergic receptor antagonist can reverse the effect.
For services to Seriously and Terminally Ill Children and their Families. Kevin Shakesheff. Co-Founder, High Tide Foundation and President, Institute of Chartered Shipbrokers and Educational Fund. For services to Young People in Business and to the Maritime Industry. Ian James Donald Sharp. Lately Captain, 6th Wolverhampton Boys' Brigade. For services to Young People in Wolverhampton. Yassamin Sheel. National Lead, United Teaching, Greater Manchester. For services to Children. Karen Eileen Shepperson. Director of People and Operations, Ofsted. For services to Education. Savraj Singh Shetra. Field Intelligence Officer, Home Office. For Public Service. Dr. Hamsaraj Gundal Mahabala Shetty. Consultant Physician, University Hospital of Wales. For services to Stroke Services in Wales. David Alan Short, JP. Lately Group Technology Director, BAE Systems. For services to Military Capability. David Norman Short. For services to Pastoral Care and to the community in Buckinghamshire. John Stanley William Simpson. For services to Agriculture and to the community in Lewes, East Sussex. Margaret Ann Simpson. For services to the community in Oxfordshire. Roselind Pamela Sinclair. Lecturer in Design Education, Goldsmiths, University of London. For services to the Arts. Nirmal Singh. Chaplain, North West Prisons HM Prison and Probation Service. For services to Community Development and Interfaith Integration. Catherine Elizabeth Skidmore. Head of Aviation Resilience, Department for Transport. For services to Major Event Responses. Christopher Jon Smith.
The Doctor of Clinical Laboratory Science (DCLS) is a professional degree in clinical laboratory science in the United States for medical laboratory scientists. The DCLS is board eligible and qualifies as a CLIA high complexity laboratory director (HCLD). Doctors of Clinical Laboratory Science may conduct research or serve on healthcare teams. DCLS work closely with physicians, catching pre- analytical, analytical, and post-analytical test and interpretation errors in order to ensure optimal patient care outcomes. Doctors of Clinical Laboratory Science complete a residency at the end of their training. There are four programs:
Sources: en.wikipedia.org
== Pharmacology == Rimonabant is an inverse agonist of the cannabinoid CB1 receptor. Originally thought to be selective for the CB1 receptor, rimonabant was subsequently also found to act as an antagonist of the μ-opioid receptor. These properties may make this drug useful in cases of cannabinoid or opioid overdose but more research and safety testing is required.
Most important to disease management is exclusion because D. dadantii can move through vegetatively propagated tissues asymptomatically. Therefore, it is important to have certified disease-free stock. Some promising biological control research is being done for orchid species. D. dadantii has been studied in commercially valuable Phalaenopsis orchids. Soft rot diseases caused by Dickeya spp is one of the most devastating diseases in orchid production. Orchid growers have used environmental controls to provide the optimum growth conditions for the plants while minimizing the cultivation of the pathogens. Proper control of humidity and air movement combined with clean, high quality water, in a temperature and light regulated facility are the most commonly employed methods for disease prevention. Other biological controls of D. dadantii include symbiotic fungi known as mycorrhiza and possibly transgenic proteins. Transfer of sweet pepper genes coding for ferredoxin like protein and defensin was shown to reduce D. dadantii disease in Phalaenopsis orchids under cultivation.
=== Center of Excellence for Transgender Health (UCSF) === The Center of Excellence for Transgender Health at the University of California, San Francisco was established in 2009, dedicated to improving health equity for trans and gender nonconforming communities. The Center of Excellence for Transgender Health is a national advisory board composed of transgender leaders from across the United States, bringing expertise in the research of transgender health. Guidelines for Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People contains guidelines developed by The Center of Excellence for Transgender Health that are widely used clinical guidelines for transgender healthcare.
=== Generation and accumulation === Biomedical waste should be collected in containers that are leak-proof and sufficiently strong to prevent breakage during handling. Containers of biomedical waste are marked with a biohazard symbol. The container, marking, and labels are often red. Discarded sharps are usually collected in specialized boxes, often called needle boxes. Specialized equipment is required to meet OSHA 29 CFR 1910.1450 and EPA 40 CFR 264.173. standards of safety. Minimal recommended equipment include a fume hood and primary and secondary waste containers to capture potential overflow. Even beneath the fume hood, containers containing chemical contaminants should remain closed when not in use. An open funnel placed in the mouth of a waste container has been shown to allow significant evaporation of chemicals into the surrounding atmosphere, which is then inhaled by laboratory personnel, and contributes a primary component to the threat of completing the fire triangle. To protect the health and safety of laboratory staff as well as neighboring civilians and the environment, proper waste management equipment, such as the Burkle funnel in Europe and the ECO Funnel in the U.S., should be utilized in any department which deals with chemical waste. It is to be dumped after treatment. Operating Rooms ORs generate around one-third of waste in a hospital. This waste includes but is not limited to biohazards, plastic materials, pharmaceuticals, and linens. Moreover, ORs require large amounts of energy, causing a further negative environmental impact.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.